OTC · CIK 0001842939
XAGE Longevity Health Holdings, Inc.
Insider trading from SEC Form 4. Last filing Apr 8, 2026. Close $0.11 on Oct 9, 2026, 0% from the 52-week low and -85% from the high.
In brief
Longevity Health Holdings, Inc. (XAGE) has 9 SEC Form 4 filings on file from 9 insiders, the latest filed on Apr 8, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at XAGE. The newest: J. Ram Ajjarapu (Chief Executive Officer) bought $200k of stock on Mar 16, 2026, filed Apr 8, 2026, scored 45 (moderate).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Longevity Health Holdings, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | J. Ram Ajjarapu Chief Executive Officer buy | $200k 689,656 shares | - | - |
Transactions
Every row filed, 9 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | J. Ram Ajjarapu Chief Executive Officer | POpen-market purchase Common Stockindirect: By International Capital Partners LLC | +689,656 | $0.29 | $200k | 689,656 | Apr 8, 2026 |
| Oct 11, 2024 | Kendra Bracken-Ferguson Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +378,705 | $0.00 | $0 | 378,705 | Nov 8, 2024 |
| Oct 11, 2024 | Scott M. Frisch director | AGrant or award Stock Option (right to buy)derivative | +76,878 | $0.00 | $0 | 76,878 | Nov 8, 2024 |
| Oct 11, 2024 | Rajiv Shukla Chairman and CEO | AGrant or award Stock Option (right to buy)derivative | +876,878 | $0.00 | $0 | 876,878 | Nov 8, 2024 |
| Oct 11, 2024 | Kathryn Gregory director | AGrant or award Stock Option (right to buy)derivative | +76,878 | $0.00 | $0 | 76,878 | Nov 8, 2024 |
| Oct 11, 2024 | Gilles Spenlehauer director | AGrant or award Stock Option (right to buy)derivative | +76,878 | $0.00 | $0 | 76,878 | Nov 8, 2024 |
| Oct 11, 2024 | Bryan J. Cassaday Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Nov 8, 2024 |
| Oct 11, 2024 | Richard A Upton director | AGrant or award Stock Option (right to buy)derivative | +76,878 | $0.00 | $0 | 76,878 | Nov 8, 2024 |
| Oct 11, 2024 | Patrick A Sturgeon director | AGrant or award Stock Option (right to buy)derivative | +76,878 | $0.00 | $0 | 76,878 | Nov 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- J. Ram AjjarapuChief Executive Officer
- Kendra Bracken-FergusonChief Executive Officer
- Bryan J. CassadayChief Financial Officer
- Scott M. Frischdirector
- Kathryn Gregorydirector
- Rajiv ShuklaChairman and CEO
- Gilles Spenlehauerdirector
- Patrick A Sturgeondirector
- Richard A Uptondirector
Questions about XAGE
Answered from the filings on this page, as of the latest one.
Are insiders buying XAGE?
No. In the last 90 days no insider at Longevity Health Holdings, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade XAGE on the open market?
J. Ram Ajjarapu (Chief Executive Officer) bought $200k of XAGE on Mar 16, 2026 and filed the Form 4 on Apr 8, 2026. InsiderTell scored 45 (moderate).
How many insiders file Form 4 at Longevity Health Holdings, Inc.?
9 people have filed a Form 4 at Longevity Health Holdings, Inc., among them J. Ram Ajjarapu (Chief Executive Officer), Kendra Bracken-Ferguson (Chief Executive Officer), Bryan J. Cassaday (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.